Open Access
Open access
Springer Nature
Drugs
,  том 82 ,  издание 6 ,  страницы 711-716

Palovarotene: First Approval

Тип публикации: Journal Article
Дата публикации: 2022-04-06
Springer Nature
scimago Q1
wos Q1
БС1
SJR: 3.362
CiteScore: 26.2
Impact factor: 14.4
ISSN: 00126667, 11791950
Pharmacology (medical)
Краткое описание
Palovarotene (Sohonos™) is an orally bioavailable selective retinoic acid receptor (RAR)γ agonist being developed by Ipsen for the reduction of heterotopic ossification (HO) formation in patients with fibrodysplasia ossificans progressiva (FOP). By binding to RARγ, palovarotene inhibits bone morphogenetic protein and SMAD 1/5/8 signalling: interfering with these pathways prevents chondrogenesis and ultimately HO by permitting normal muscle tissue repair or regeneration to occur. Palovarotene received its first approval on 21 January 2022 to reduce the formation of HO in adults and children aged 8 years and above for females and 10 years and above for males with FOP in Canada. This article summarizes the milestones in the development of palovarotene leading to this first approval.
Найдено 
Найдено 

Топ-30

Журналы

1
2
3
Journal of Medicinal Chemistry
Journal of Medicinal Chemistry, 3, 12.5%
Journal of Medicinal Chemistry
3 публикации, 12.5%
European Journal of Medicinal Chemistry
European Journal of Medicinal Chemistry, 3, 12.5%
European Journal of Medicinal Chemistry
3 публикации, 12.5%
International Journal of Molecular Sciences
International Journal of Molecular Sciences, 2, 8.33%
International Journal of Molecular Sciences
2 публикации, 8.33%
iScience
iScience, 2, 8.33%
iScience
2 публикации, 8.33%
Stem Cell Research and Therapy
Stem Cell Research and Therapy, 1, 4.17%
Stem Cell Research and Therapy
1 публикация, 4.17%
Frontiers in Pediatrics
Frontiers in Pediatrics, 1, 4.17%
Frontiers in Pediatrics
1 публикация, 4.17%
Frontiers in Endocrinology
Frontiers in Endocrinology, 1, 4.17%
Frontiers in Endocrinology
1 публикация, 4.17%
RSC Medicinal Chemistry
RSC Medicinal Chemistry, 1, 4.17%
RSC Medicinal Chemistry
1 публикация, 4.17%
Genes
Genes, 1, 4.17%
Genes
1 публикация, 4.17%
EFORT Open Reviews
EFORT Open Reviews, 1, 4.17%
EFORT Open Reviews
1 публикация, 4.17%
N N Priorov Journal of Traumatology and Orthopedics
N N Priorov Journal of Traumatology and Orthopedics, 1, 4.17%
N N Priorov Journal of Traumatology and Orthopedics
1 публикация, 4.17%
Expert Opinion on Pharmacotherapy
Expert Opinion on Pharmacotherapy, 1, 4.17%
Expert Opinion on Pharmacotherapy
1 публикация, 4.17%
Journal of Orthopaedic Research
Journal of Orthopaedic Research, 1, 4.17%
Journal of Orthopaedic Research
1 публикация, 4.17%
Chinese Medical Journal
Chinese Medical Journal, 1, 4.17%
Chinese Medical Journal
1 публикация, 4.17%
The Innovation
The Innovation, 1, 4.17%
The Innovation
1 публикация, 4.17%
Biosciences Biotechnology Research Asia, 1, 4.17%
Biosciences Biotechnology Research Asia
1 публикация, 4.17%
Bone
Bone, 1, 4.17%
Bone
1 публикация, 4.17%
Biomolecules
Biomolecules, 1, 4.17%
Biomolecules
1 публикация, 4.17%
1
2
3

Издатели

1
2
3
4
5
6
7
Elsevier
Elsevier, 7, 29.17%
Elsevier
7 публикаций, 29.17%
MDPI
MDPI, 4, 16.67%
MDPI
4 публикации, 16.67%
American Chemical Society (ACS)
American Chemical Society (ACS), 3, 12.5%
American Chemical Society (ACS)
3 публикации, 12.5%
Frontiers Media S.A.
Frontiers Media S.A., 2, 8.33%
Frontiers Media S.A.
2 публикации, 8.33%
Springer Nature
Springer Nature, 1, 4.17%
Springer Nature
1 публикация, 4.17%
Royal Society of Chemistry (RSC)
Royal Society of Chemistry (RSC), 1, 4.17%
Royal Society of Chemistry (RSC)
1 публикация, 4.17%
Bioscientifica
Bioscientifica, 1, 4.17%
Bioscientifica
1 публикация, 4.17%
Eco-Vector LLC
Eco-Vector LLC, 1, 4.17%
Eco-Vector LLC
1 публикация, 4.17%
Taylor & Francis
Taylor & Francis, 1, 4.17%
Taylor & Francis
1 публикация, 4.17%
Wiley
Wiley, 1, 4.17%
Wiley
1 публикация, 4.17%
Ovid Technologies (Wolters Kluwer Health)
Ovid Technologies (Wolters Kluwer Health), 1, 4.17%
Ovid Technologies (Wolters Kluwer Health)
1 публикация, 4.17%
Oriental Scientific Publishing Company, 1, 4.17%
Oriental Scientific Publishing Company
1 публикация, 4.17%
1
2
3
4
5
6
7
  • Мы не учитываем публикации, у которых нет DOI.
  • Статистика публикаций обновляется еженедельно.

Вы ученый?

Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
Метрики
24
Поделиться
Цитировать
ГОСТ |
Цитировать
ГОСТ Скопировать
Hoy S. M. Palovarotene: First Approval // Drugs. 2022. Vol. 82. No. 6. pp. 711-716.
ГОСТ со всеми авторами (до 50) Скопировать
Hoy S. M. Palovarotene: First Approval // Drugs. 2022. Vol. 82. No. 6. pp. 711-716.
RIS |
Цитировать
RIS Скопировать
TY - JOUR
DO - 10.1007/s40265-022-01709-z
UR - https://doi.org/10.1007/s40265-022-01709-z
TI - Palovarotene: First Approval
T2 - Drugs
AU - Hoy, Sheridan M.
PY - 2022
DA - 2022/04/06
PB - Springer Nature
SP - 711-716
IS - 6
VL - 82
PMID - 35384641
SN - 0012-6667
SN - 1179-1950
ER -
BibTex |
Цитировать
BibTex (до 50 авторов) Скопировать
@article{2022_Hoy,
author = {Sheridan M. Hoy},
title = {Palovarotene: First Approval},
journal = {Drugs},
year = {2022},
volume = {82},
publisher = {Springer Nature},
month = {apr},
url = {https://doi.org/10.1007/s40265-022-01709-z},
number = {6},
pages = {711--716},
doi = {10.1007/s40265-022-01709-z}
}
MLA
Цитировать
MLA Скопировать
Hoy, Sheridan M.. “Palovarotene: First Approval.” Drugs, vol. 82, no. 6, Apr. 2022, pp. 711-716. https://doi.org/10.1007/s40265-022-01709-z.